PTO/SB/08b (08-03)
Approved for use through 08/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
of a collection of information unless it contains a waited OMB water.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RADENSE for form 1449B/PTO Complet if Known Application Number 10/010,802 INFORMATION DISCLOSURE Filing Date 11/09/2001 STATEMENT BY APPLICANT First Named Inventor Anne Chew Art Unit 1634 (Use as many sheets as necessary) Examiner Name Juliet C. Switzer Attorney Docket Number | MWH-0002US2 Sheet 2

	NON PATENT LITERATURE DOCUMENTS				
Initials* magazine, journal, serial, symposium, ca		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
gh		COLLINS A ET AL., "Genetic epidemiology of single-nucleotide polymorphisms," Proc. Natl. Acad. Sci USA, Vol. 96 (No. 26), p. 15173-77, (December 21, 1999).			
× (×		CLARK AG, "Inference of Haplotypes from PCR-amplified Samples of Diploid Populatons," Mol Biol Evol, Vol. 7 (No. 2), p. 111-22, (1990).			
	٠.	DEVLIN, B. AND RISCH, N., "A Comparison of Linkage Disequilibrium Measures for Fine Scale Mapping," Genomics, Vol. 29, p. 311-22, (1995).			
		HAWLEY ME AND KIDD KK, "HAPLO: A Program Using the EM Algorithm to Estimate the Frequencies of Multi-site Haplotypes," J. Heredity, Vol. 86 (No. 5), p. 409-411, (1995).			
		KRUGLYAK L., "Prospects for whole-genome linkage disequilibrium mapping of common disease genes," Nature Genetics, Vol 22, p. 139-44, (June 1999).			
		HACKSTEIN, H. ET AL., "Definition of Human Interleukin-4 Receptor Alpha Chain Haplotypes and Allelic Association with Atopy Markers," Human Immunology, Vol. 60, p. 1119-1127, (1999).			
		OBER C ET AL., "Variation in the Interleukin-4-Receptor alpha Gene Confers Susceptibility to Asthma and Atopy in Ethnically Diverse Populations," Am. J. Hum Genet, Vol. 66, p. 517-526, (February 3, 2000).			
		RIEDER MJ ET AL., "Sequence variation in the human angiotensin converting enzyme," Nature Genetics, Vol. 22, p. 59-62, (May 1999).			
4		TAILLON-MILLER P. ET AL., "Juxtaposed regions of extensive and minimal linkage disequilibrium in human Xq25 and Xq28," Nature Genetics, Vol. 25, p. 324-28, (July 2000).			
ab		WEIR B.S., Genetic Data Analysis II, Sinauer Associates, Inc. Publishers (Sunderland, MA), p. 112-133, (1996).			

	Examiner Signature	gontye.	Date Considered	415/04
--	-----------------------	---------	--------------------	--------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Al xandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

er the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

Sheet

NOV 1 4 2003

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

2

2

Complete if Known					
Application Number	10/010,802				
Filing Date	11/09/2001				
First Named Inventor	Anne Chew				
Art Unit	1634				
Examiner Name	Juliet C. Switzer				
Attomey Docket Number					

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. DUNNING AM ET AL., "The Extent of Linkage Disequilibrium in Four Populations with Distinct Demographic Histories," Am. J. Hum Genet, Vol. 67, p. 1544-1554, (November 14, 2000).			
B					

	\bigcap \bigwedge		
Examiner	1 Marken	Date	l 11///al
Signature	7)XW\\\\\\\	 Considered	1 1115104

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

¹ Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: C mmission r for Pat nts, P.O. B x 1450, Al xandria, VA 22313-1450.

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE er the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

US-US-

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary

of

Complete if Known **Application Number** 10/010.802 Filing Date 11/09/2001 First Named Inventor Anne Chew Art Unit 1634 **Examiner Name** Juliet C. Switzer Attorney Docket Number MWH-002US2

U. S. PATENT DOCUMENTS Examiner Cite **Publication Date** Name of Patentee or Document Number Pages, Columns, Lines, Where MM-DD-YYYY Initials* Applicant of Cited Document Relevant Passages or Relevant Figures Appear Number-Kind Code^{2 (# known)} US-US-US-US-US-US-US-US-US-US-US-US-US-US-US-US-

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code 3- Number 4- Kind Code 5 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T,
(h)		WO/01/80156	10/25/2001	Genaissance Pharmaceuticals, Inc.		
						-

Examiner		Date	11 ml. (1)	
Signature	Chanton	Considered	1 1119104	
- Griginaliana		Considered	1000	

*EXAMINER: Initial if beference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include clopy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, 15 kind of document the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.